Opinion|Videos|October 11, 2024

Complement Inhibitors in NMOSD

Key Takeaways

  • Ravulizumab, a complement inhibitor, is FDA-approved for NMOSD, offering a longer half-life than eculizumab, allowing for extended dosing intervals.
  • The standard dosing regimen for ravulizumab includes an initial loading dose followed by maintenance doses every eight weeks.
SHOW MORE

Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.

Episodes in this series

Video content above is prompted by the following:

  1. Where do complement inhibitors fit in the treatment landscape of neuromyelitis optica spectrum disorder (NMOSD)? Which complement inhibitors are approved for NMOSD?
  2. Please provide an overview of ravulizumab, the most recent FDA-approved treatment for NMOSD, the rationale for its development, half-life, and dosing regimen.
  3. Long-term extension (138-week) data with ravulizumab were recently presented at EAN 2024. 
  4. Are there any new signals in the long-term extension study?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

View more
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

View more
Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier
Video

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

View more
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
Video

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

View more
PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

View more
PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

View more